Advanced/Metastatic Clinical Trials

1 recruiting

Advanced/Metastatic Trials at a Glance

24 actively recruiting trials for advanced/metastatic are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 1 with 18 trials, with the heaviest enrollment activity in Houston, Nashville, and Denver. Lead sponsors running advanced/metastatic studies include Pfizer, Shanghai Henlius Biotech, and Bayer.

Browse advanced/metastatic trials by phase

Treatments under study

About Advanced/Metastatic Clinical Trials

Looking for clinical trials for Advanced/Metastatic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced/Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced/Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Advanced/Metastatic Colorectal Adenocarcinoma
Bayer130 enrolled21 locationsNCT07535112
Recruiting
Phase 1Phase 2

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Urothelial CarcinomaUrothelial CancerAdvanced/Metastatic Urothelial Cancer
Pfizer132 enrolled40 locationsNCT07421700
Recruiting
Phase 1Phase 2

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Carcinoma, Non-Small Cell LungAdvanced/Metastatic Non-Small Cell Lung Cancer
Pfizer162 enrolled32 locationsNCT07227298
Recruiting
Phase 2

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

PembrolizumabPhase 2Zanzalintinib+1 more
M.D. Anderson Cancer Center20 enrolled1 locationNCT07283731
Recruiting
Phase 1

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Antengene Biologics Limited156 enrolled22 locationsNCT05718895
Recruiting
Phase 1

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
DualityBio Inc.233 enrolled6 locationsNCT07141706
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Urothelial CarcinomaBladder CancerAdvanced/Metastatic Solid Tumors+1 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

HER2-positive Breast CancerBreast Cancer (Advanced/Metastatic)
Beijing Biotech60 enrolled1 locationNCT07510802
Recruiting
Phase 2

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Advanced/Metastatic Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals300 enrolled1 locationNCT07154290
Recruiting
Early Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

NSCLCAdvanced/Metastatic Solid Tumors
Shanghai Henlius Biotech254 enrolled2 locationsNCT07274813
Recruiting
Phase 1Phase 2

Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.820 enrolled1 locationNCT07415863
Recruiting

Praegnant Breast Cancer: Early/Advanced/Metastatic

Breast Cancer (Early Breast Cancer)Advanced/Metastatic Breast Cancer
University Hospital Tuebingen13,500 enrolled61 locationsNCT02338167
Recruiting
Phase 1Phase 2

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Adagene Inc186 enrolled21 locationsNCT05405595
Recruiting
Phase 1

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited80 enrolled9 locationsNCT06414460
Recruiting
Phase 2

Impact of Circadian Rhythm on Immunotherapy

Advanced/Metastatic NSCLC
Liza Villaruz, MD350 enrolled1 locationNCT07224971
Recruiting
Phase 1

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech340 enrolled2 locationsNCT06115642
Recruiting
Phase 1

Study of ESG406 in Adults With Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd556 enrolled3 locationsNCT06979674
Recruiting
Phase 1Phase 2

Study of MHB088C for Patients With Advanced Solid Malignant Tumors

Advanced/Metastatic Solid Tumors
Qilu Pharmaceutical Co., Ltd.515 enrolled1 locationNCT07102004
Recruiting
Phase 3

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

NSCLC (Non-small Cell Lung Carcinoma)First Line TherapyLocally Advanced/Metastatic NSCLC
Dr Arvindran A/L Alaga123 enrolled1 locationNCT07050043
Recruiting
Phase 1Phase 2

A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.120 enrolled1 locationNCT06922357